Amicus Therapeutics Stock News

Amicus (FOLD) misses both Q3 earnings and revenue estimates. Resultantly, the stock price falls.

Amicus Therapeutics' (FOLD) CEO John Crowley on Q3 2021 Results - Earnings Call Transcript

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -5.56% and -2.30%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock

The consensus price target hints at a 77.1% upside potential for Amicus Therapeutics (FOLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnin

It has been a rocky year for Amicus Therapeutics, Inc. (NASDAQ:FOLD), after the stock suffered a dramatic bear gap back in February that it hasn't even come close to recovering from.

Amicus Therapeutics announced the formation of Caritas Therapeutics, consisting of Amicus' gene therapy portfolio.

New York, New York--(Newsfile Corp. - October 4, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Amicus Therapeutics, Inc. (NASDAQ: F

Amicus (FOLD) plans to separate its gene therapy business into a new company formed in alliance with ARYA Sciences Acquisition Corp.

Shares of Amicus Therapeutics Inc. FOLD, -5.11% were up 5.6% in premarket trading on Thursday, the day after the company announced a deal to sell its gene therapy business to ARYA Sciences Acquisition

Amicus Therapeutics, Inc. (FOLD) on Formation of Caritas Therapeutics Conference Call (Transcript)

Amicus Therapeutics Inc (NASDAQ: FOLD) has agreed to spin off its gene therapy business to Sciences Acquisition Corp IV (NASDAQ: ARYD) and launch genetic medicine company Caritas Therapeutics In

The FDA has accepted for review Amicus Therapeutics Inc's (NASDAQ: FOLD) Biologics License Application (BLA) for cipaglucosidase alfa and the New Drug Application (NDA) for miglustat for AT-GAA. Al

Business Combination of Amicus Gene Therapy Business with ARYA IV to Result  in the Launch of Caritas Therapeutics, a New Independent, Publicly Traded Company  with Expected ~$400M in Initial Fundin

PHILADELPHIA, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in upcoming presentations at the

Amicus Therapeutics, Inc. (FOLD) CEO John Crowley on Q2 2021 Results - Earnings Call Transcript